Prostate-Specific Antigen Velocity Risk Count Assessment

A New Concept for Detection of Life-Threatening Prostate Cancer During Window of Curability

H. Ballentine Carter, Anna Kettermann, Luigi Ferrucci, Patricia Landis, E. Metter

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Objectives: To determine whether the number of times the prostate-specific antigen (PSA) velocity (PSAV) exceeds a threshold (PSAV risk count) is predictive of high-risk prostate cancer. Methods: The PSAV was determined in 717 men (606 without prostate cancer; 32 with high-risk prostate cancer defined as death from cancer, PSA level of 20 ng/mL or more, or a Gleason score of 8 or more; and 79 with prostate cancer who were alive or dead of another cause). Multiple PSAVs determined from three repeated measures from each subject during 10 to 20 years were used to determine the risk count by summing the number of times a subject exceeded a PSAV threshold. Cox proportional hazards regression analysis was used to evaluate the associations between the risk count and the probability of high-risk disease. The statistical tests were two-sided. Results: The probability of high-risk disease increased directly with the risk count. After adjusting for age, PSA level, PSAV, and date of diagnosis, the PSAV risk count was significantly associated with the development of high-risk prostate cancer (relative risk 1.41, 95% confidence interval 1.25 to 1.59 for a PSAV cutpoint 0.2 ng/mL/yr; relative risk 1.49, 95% confidence interval 1.29 to 1.71 for a PSAV cutpoint of 0.4 ng/mL/yr; P <0.001). Conclusions: The PSAV risk count could be a useful method of interpreting a PSA history to help identify those men who will benefit from a diagnosis of prostate cancer at PSA levels associated with curable disease.

Original languageEnglish (US)
Pages (from-to)685-690
Number of pages6
JournalUrology
Volume70
Issue number4
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Confidence Intervals
Neoplasm Grading
History
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Prostate-Specific Antigen Velocity Risk Count Assessment : A New Concept for Detection of Life-Threatening Prostate Cancer During Window of Curability. / Carter, H. Ballentine; Kettermann, Anna; Ferrucci, Luigi; Landis, Patricia; Metter, E.

In: Urology, Vol. 70, No. 4, 01.10.2007, p. 685-690.

Research output: Contribution to journalArticle

Carter, H. Ballentine ; Kettermann, Anna ; Ferrucci, Luigi ; Landis, Patricia ; Metter, E. / Prostate-Specific Antigen Velocity Risk Count Assessment : A New Concept for Detection of Life-Threatening Prostate Cancer During Window of Curability. In: Urology. 2007 ; Vol. 70, No. 4. pp. 685-690.
@article{cfbf8f5b293c47eaa6662bd795bd24b0,
title = "Prostate-Specific Antigen Velocity Risk Count Assessment: A New Concept for Detection of Life-Threatening Prostate Cancer During Window of Curability",
abstract = "Objectives: To determine whether the number of times the prostate-specific antigen (PSA) velocity (PSAV) exceeds a threshold (PSAV risk count) is predictive of high-risk prostate cancer. Methods: The PSAV was determined in 717 men (606 without prostate cancer; 32 with high-risk prostate cancer defined as death from cancer, PSA level of 20 ng/mL or more, or a Gleason score of 8 or more; and 79 with prostate cancer who were alive or dead of another cause). Multiple PSAVs determined from three repeated measures from each subject during 10 to 20 years were used to determine the risk count by summing the number of times a subject exceeded a PSAV threshold. Cox proportional hazards regression analysis was used to evaluate the associations between the risk count and the probability of high-risk disease. The statistical tests were two-sided. Results: The probability of high-risk disease increased directly with the risk count. After adjusting for age, PSA level, PSAV, and date of diagnosis, the PSAV risk count was significantly associated with the development of high-risk prostate cancer (relative risk 1.41, 95{\%} confidence interval 1.25 to 1.59 for a PSAV cutpoint 0.2 ng/mL/yr; relative risk 1.49, 95{\%} confidence interval 1.29 to 1.71 for a PSAV cutpoint of 0.4 ng/mL/yr; P <0.001). Conclusions: The PSAV risk count could be a useful method of interpreting a PSA history to help identify those men who will benefit from a diagnosis of prostate cancer at PSA levels associated with curable disease.",
author = "Carter, {H. Ballentine} and Anna Kettermann and Luigi Ferrucci and Patricia Landis and E. Metter",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.urology.2007.05.010",
language = "English (US)",
volume = "70",
pages = "685--690",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Prostate-Specific Antigen Velocity Risk Count Assessment

T2 - A New Concept for Detection of Life-Threatening Prostate Cancer During Window of Curability

AU - Carter, H. Ballentine

AU - Kettermann, Anna

AU - Ferrucci, Luigi

AU - Landis, Patricia

AU - Metter, E.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Objectives: To determine whether the number of times the prostate-specific antigen (PSA) velocity (PSAV) exceeds a threshold (PSAV risk count) is predictive of high-risk prostate cancer. Methods: The PSAV was determined in 717 men (606 without prostate cancer; 32 with high-risk prostate cancer defined as death from cancer, PSA level of 20 ng/mL or more, or a Gleason score of 8 or more; and 79 with prostate cancer who were alive or dead of another cause). Multiple PSAVs determined from three repeated measures from each subject during 10 to 20 years were used to determine the risk count by summing the number of times a subject exceeded a PSAV threshold. Cox proportional hazards regression analysis was used to evaluate the associations between the risk count and the probability of high-risk disease. The statistical tests were two-sided. Results: The probability of high-risk disease increased directly with the risk count. After adjusting for age, PSA level, PSAV, and date of diagnosis, the PSAV risk count was significantly associated with the development of high-risk prostate cancer (relative risk 1.41, 95% confidence interval 1.25 to 1.59 for a PSAV cutpoint 0.2 ng/mL/yr; relative risk 1.49, 95% confidence interval 1.29 to 1.71 for a PSAV cutpoint of 0.4 ng/mL/yr; P <0.001). Conclusions: The PSAV risk count could be a useful method of interpreting a PSA history to help identify those men who will benefit from a diagnosis of prostate cancer at PSA levels associated with curable disease.

AB - Objectives: To determine whether the number of times the prostate-specific antigen (PSA) velocity (PSAV) exceeds a threshold (PSAV risk count) is predictive of high-risk prostate cancer. Methods: The PSAV was determined in 717 men (606 without prostate cancer; 32 with high-risk prostate cancer defined as death from cancer, PSA level of 20 ng/mL or more, or a Gleason score of 8 or more; and 79 with prostate cancer who were alive or dead of another cause). Multiple PSAVs determined from three repeated measures from each subject during 10 to 20 years were used to determine the risk count by summing the number of times a subject exceeded a PSAV threshold. Cox proportional hazards regression analysis was used to evaluate the associations between the risk count and the probability of high-risk disease. The statistical tests were two-sided. Results: The probability of high-risk disease increased directly with the risk count. After adjusting for age, PSA level, PSAV, and date of diagnosis, the PSAV risk count was significantly associated with the development of high-risk prostate cancer (relative risk 1.41, 95% confidence interval 1.25 to 1.59 for a PSAV cutpoint 0.2 ng/mL/yr; relative risk 1.49, 95% confidence interval 1.29 to 1.71 for a PSAV cutpoint of 0.4 ng/mL/yr; P <0.001). Conclusions: The PSAV risk count could be a useful method of interpreting a PSA history to help identify those men who will benefit from a diagnosis of prostate cancer at PSA levels associated with curable disease.

UR - http://www.scopus.com/inward/record.url?scp=35649019175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35649019175&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.05.010

DO - 10.1016/j.urology.2007.05.010

M3 - Article

VL - 70

SP - 685

EP - 690

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -